I2 Pharmaceuticals, Inc.

Sea Lane Biotechnologies, LLC

Lawrence C Horowitz

Ramesh Bhatt

Arun K Kashyap

Li Xu

Aaron L Kurtzman

Michael D Horowitz

Pamela K Foreman

Charles H Hannum

Medini Gore

Phil Kobel

Sihong Zhou

Ryann E O'Neil

Danying Cai

Pamela Foreman

The present invention concerns anti-surrogate light chain antibodies and their uses. In particular, the present invention concerns anti-VpreB1 antibodies and their uses.

Anti-surrogate light chain antibodies

Embodiments concern constructs comprising surrogate light chain sequences. In particular, embodiments concern constructs that can bind to ErbB3 and aspects relating to such constructs.

Sur-binding proteins against ERBB3

The present invention concerns the design and construction of diverse peptide and polypeptide libraries. In particular, the invention concerns methods of analytical database design for creating datasets using multiple relevant parameters as filters, and methods for generating sequence diversity by directed multisyntheses oligonucleotide synthesis. The present methods enable the reduction of large complex annotated databases to simpler datasets of related sequences, based upon relevant single or multiple key parameters that can be individually directly defined. The methods further enable the creation of diverse libraries based on this approach, using multisynthetic collections of discrete and degenerate oligonucleotides to capture the diverse collection of sequences, or portions thereof.

Construction of diverse synthetic peptide and polypeptide libraries

The invention concerns constructs and libraries comprising antibody surrogate light chain sequences. In particular, the invention concerns constructs comprising VpreB sequences, optionally partnered with another polypeptide, such as, for example, antibody heavy chain variable domain sequences, and libraries containing the same.

Constructs and libraries comprising antibody surrogate light chain sequences

The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza A viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza A virus subtypes, and methods and means for making such antibodies.

Neutralizing molecules to influenza viruses

Embodiments concern constructs comprising surrogate light chain sequences. In particular, embodiments concern constructs that can bind to DR4 and/or DR5 and aspects relating to such constructs and their use.

Surrogate binding proteins which bind DR4 and/or DR5

The present invention concerns methods and means for identifying, producing, and engineering neutralizing molecules against influenza A viruses, and to the neutralizing molecules produced. In particular, the invention concerns neutralizing molecules against various influenza A virus subtypes, including neutralizing antibodies against H5 and/or H3 and/or H1, such as, for example all of H1, H3, and H5 subtypes, and methods and means for making such molecules.

Neutralizing molecules to viral antigens

The present invention concerns surrogate light chain (SURROBODY&#x2122;) constructs comprising surrogate light chain sequences with heterologous signal sequences.

Expression of surrogate light chains

The present invention concerns donor-specific antibody libraries derived from a patient donor who has suffered from, or is suffering from one or more diseases discussed herein. The present invention also concerns the method of making and using the donor-specific antibodies. The present invention further concerns the neutralizing antibodies obtained from the donor-specific antibody libraries and the methods of using these antibodies for the prevention/treatment of human disease.

Growing community of inventors

Atherton, CA, United States of America

Lawrence C Horowitz